[Prognostic Value of LMR and CD163+TAM for Patients with Diffuse Large B Cell Lymphoma].

Abstract

Objective: To investigate the prognostic value of lymphocyte-to-monocyte ratio (LMR) and CD163⁺tumor-associated macrophages (TAM) in patients with diffuse large B cell lymphoma (DLBCL).

Methods: Peripheral blood and lymph node tissues were collected from 63 newly diagnosed DLBCL patients. LMR was calculated by the number of lymphocytes and monocytes in peripheral blood from the result of blood routine examination. The level of CD163⁺TAM in lymph nodes was detected by immunohistochemistry. The cut-off values of LMR and CD163⁺TAM were determined by ROC curves, and the prognostic value of LMR and CD163⁺TAM in DLBCL patients was analyzed.

Results: The LMR level of 63 newly diagnosed DLBCL patients was 3.69±1.71, and the median value of CD163⁺TAM was 26/HPF. The number of CD163⁺TAM was negatively correlated with LMR (r =-0.58) and positively correlated with monocyte count (r =0.46). The cut-off values of LMR and CD163⁺TAM determined by ROC curve were 2.95 and 29/HPF, respectively, and based on this, the patients were divided into low LMR group and high LMR group, as well as low CD163⁺TAM group and high CD163⁺TAM group. The proportion of patients with clinical stage III-IV, IPI score 3-5 and bone marrow infiltration in the low LMR group were higher than those in the high LMR group (P < 0.05). The proportion of patients with clinical stage III-IV, IPI score 3-5, elevated LDH level and bone marrow infiltration in the high CD163⁺TAM group were higher than those in the low CD163⁺TAM group (P < 0.05). There was a positive correlation between LMR and OS (r =0.43) and a negative correlation between CD163⁺TAM and OS (r =-0.65). DLBCL patients with low LMR and high CD163⁺TAM had shorter OS (P < 0.05).

Conclusion: Low LMR and high CD163⁺TAM can be used as biological markers for poor prognosis of DLBCL patients.